BR0309746A - uso terapêutico de inibidores seletivos de pde10 - Google Patents
uso terapêutico de inibidores seletivos de pde10Info
- Publication number
- BR0309746A BR0309746A BRPI0309746-3A BR0309746A BR0309746A BR 0309746 A BR0309746 A BR 0309746A BR 0309746 A BR0309746 A BR 0309746A BR 0309746 A BR0309746 A BR 0309746A
- Authority
- BR
- Brazil
- Prior art keywords
- present
- selective
- relates
- disorders
- selective pde10
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229960001789 papaverine Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,183 US20030018047A1 (en) | 2001-04-20 | 2002-05-03 | Therapeutic use of selective PDE10 inhibitors |
| US10/177,018 US20030032579A1 (en) | 2001-04-20 | 2002-06-20 | Therapeutic use of selective PDE10 inhibitors |
| PCT/IB2003/001684 WO2003093499A2 (en) | 2002-05-03 | 2003-04-22 | Therapeutic use of selective pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309746A true BR0309746A (pt) | 2007-03-27 |
Family
ID=29406263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309746-3A BR0309746A (pt) | 2002-05-03 | 2003-04-22 | uso terapêutico de inibidores seletivos de pde10 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030032579A1 (OSRAM) |
| EP (1) | EP1504118A2 (OSRAM) |
| JP (1) | JP2005524402A (OSRAM) |
| KR (1) | KR20040106455A (OSRAM) |
| CN (1) | CN1668761A (OSRAM) |
| AU (1) | AU2003222395A1 (OSRAM) |
| BR (1) | BR0309746A (OSRAM) |
| CA (1) | CA2484600A1 (OSRAM) |
| HR (1) | HRP20041029A2 (OSRAM) |
| IL (1) | IL164778A0 (OSRAM) |
| MX (1) | MXPA04010777A (OSRAM) |
| NO (1) | NO20044470L (OSRAM) |
| PL (1) | PL373943A1 (OSRAM) |
| RU (1) | RU2303259C2 (OSRAM) |
| TW (1) | TWI269812B (OSRAM) |
| WO (1) | WO2003093499A2 (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060030483A (ko) * | 2003-06-30 | 2006-04-10 | 알타나 파마 아게 | Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린 |
| CA2530114A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| JP2007523152A (ja) * | 2004-02-18 | 2007-08-16 | ファイザー・プロダクツ・インク | キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体 |
| EP1755611A1 (en) * | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| US7576080B2 (en) * | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| EA012211B1 (ru) * | 2005-01-07 | 2009-08-28 | Пфайзер Продактс Инк. | Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10 |
| ATE430148T1 (de) * | 2005-01-12 | 2009-05-15 | Nycomed Gmbh | Neue pyrrolodihydroisochinoline als pde10- inhibitoren |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US20100056791A1 (en) * | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| US20090318385A1 (en) * | 2006-09-06 | 2009-12-24 | Yasushi Kohno | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient |
| US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| WO2008119057A2 (en) * | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
| US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
| WO2009068320A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| WO2009070584A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| WO2010145668A1 (en) | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
| BRPI0914772A2 (pt) | 2008-06-25 | 2015-10-20 | Envivo Pharmaceuticals Inc | compostos heterocíclicos 1,2-dissubstituídos |
| WO2010006130A2 (en) | 2008-07-09 | 2010-01-14 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
| CN102143752B (zh) | 2008-08-05 | 2014-12-10 | 奥默罗斯公司 | Pde10抑制剂以及相关组合物和方法 |
| EP2348018A4 (en) * | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE |
| US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
| CA2761032A1 (en) | 2009-05-07 | 2010-11-11 | Envivo Pharmaceuticals, Inc. | Phenoxymethyl heterocyclic compounds |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010138833A1 (en) | 2009-05-29 | 2010-12-02 | Wyeth | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| NZ601967A (en) | 2010-03-12 | 2015-03-27 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| BR112014011173A2 (pt) | 2011-11-09 | 2017-05-09 | Abbvie Deutschland | carboxamidas heterocíclicas úteis como inibidores de fosfodiesterase tipo 10a |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| RU2657540C2 (ru) * | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| IN2015DN01900A (OSRAM) | 2012-09-17 | 2015-08-07 | Abbvie Deutschland | |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| HUE043059T2 (hu) | 2013-02-27 | 2019-07-29 | Mochida Pharm Co Ltd | Új pirazolszármazék |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| WO2014140184A1 (en) | 2013-03-14 | 2014-09-18 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| CN107530313A (zh) | 2015-04-24 | 2018-01-02 | 奥默罗斯公司 | Pde10抑制剂以及相关组合物和方法 |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
| CN110346004B (zh) * | 2019-08-16 | 2020-08-21 | 杭州山科智能科技股份有限公司 | 一种双声道超声时差法的流量测量数据融合方法 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| MX2022015400A (es) * | 2020-06-05 | 2023-03-16 | Noema Pharma Ag | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette. |
| WO2022162193A1 (en) * | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| DE3224100A1 (de) * | 1982-06-29 | 1983-12-29 | Michael 6950 Schriesheim Long | Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen |
| EP0627219A1 (en) * | 1993-05-25 | 1994-12-07 | Daiichi Pharmaceutical Co., Ltd. | Use of calmodulin inhibitors for neuroprotection |
| US5487976A (en) * | 1993-10-15 | 1996-01-30 | Cornell Research Foundation, Inc. | DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells |
| US20040152106A1 (en) * | 1999-10-07 | 2004-08-05 | Robertson Harold A. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| ES2256415T3 (es) * | 2001-07-31 | 2006-07-16 | Pfizer Products Inc. | Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a. |
-
2002
- 2002-06-20 US US10/177,018 patent/US20030032579A1/en not_active Abandoned
-
2003
- 2003-04-22 AU AU2003222395A patent/AU2003222395A1/en not_active Abandoned
- 2003-04-22 HR HRP20041029 patent/HRP20041029A2/xx not_active Application Discontinuation
- 2003-04-22 CN CNA038095335A patent/CN1668761A/zh active Pending
- 2003-04-22 MX MXPA04010777A patent/MXPA04010777A/es unknown
- 2003-04-22 CA CA002484600A patent/CA2484600A1/en not_active Abandoned
- 2003-04-22 KR KR10-2004-7017684A patent/KR20040106455A/ko not_active Ceased
- 2003-04-22 BR BRPI0309746-3A patent/BR0309746A/pt not_active IP Right Cessation
- 2003-04-22 EP EP03717481A patent/EP1504118A2/en not_active Withdrawn
- 2003-04-22 JP JP2004501635A patent/JP2005524402A/ja active Pending
- 2003-04-22 RU RU2004132198/15A patent/RU2303259C2/ru not_active IP Right Cessation
- 2003-04-22 WO PCT/IB2003/001684 patent/WO2003093499A2/en not_active Ceased
- 2003-04-22 PL PL03373943A patent/PL373943A1/xx not_active Application Discontinuation
- 2003-04-28 TW TW092109924A patent/TWI269812B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/779,212 patent/US20040162294A1/en not_active Abandoned
- 2004-10-20 NO NO20044470A patent/NO20044470L/no not_active Application Discontinuation
- 2004-10-21 IL IL16477804A patent/IL164778A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003093499A2 (en) | 2003-11-13 |
| KR20040106455A (ko) | 2004-12-17 |
| IL164778A0 (en) | 2005-12-18 |
| CN1668761A (zh) | 2005-09-14 |
| RU2303259C2 (ru) | 2007-07-20 |
| US20040162294A1 (en) | 2004-08-19 |
| HRP20041029A2 (en) | 2004-12-31 |
| WO2003093499A3 (en) | 2004-04-22 |
| EP1504118A2 (en) | 2005-02-09 |
| PL373943A1 (en) | 2005-09-19 |
| MXPA04010777A (es) | 2005-03-07 |
| NO20044470L (no) | 2004-11-04 |
| AU2003222395A1 (en) | 2003-11-17 |
| CA2484600A1 (en) | 2003-11-13 |
| TW200307751A (en) | 2003-12-16 |
| US20030032579A1 (en) | 2003-02-13 |
| TWI269812B (en) | 2007-01-01 |
| JP2005524402A (ja) | 2005-08-18 |
| RU2004132198A (ru) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003093499A3 (en) | Therapeutic use of selective pde10 inhibitors | |
| EP1250923A3 (en) | Use of selective PDE10 inhibitors for the treatment of central nervous system disorders | |
| EP1755654A4 (en) | METHOD AND SYSTEMS FOR TREATING NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
| GT200800265A (es) | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. | |
| DE602006008456D1 (de) | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen | |
| EP1133294A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, DAMAGE TO THE CENTRAL NERVOUS SYSTEM AND INFLAMMATORY DISEASES | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| BRPI0512864A (pt) | composições e métodos para o tratamento de condições e desordens oculares | |
| BR0017075A (pt) | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa | |
| BR9809115A (pt) | Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt | |
| BRPI0413582A (pt) | compostos, composições e métodos para inibir a atividade de proteasome | |
| ATE443758T1 (de) | Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| DE60324449D1 (de) | Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie | |
| Massot et al. | Magnetic field desensitizes 5-HT1B receptor in brain: pharmacological and functional studies | |
| IL132293A0 (en) | Use of lactoferin in the treatment of allergen induced disorders | |
| BRPI0417520A (pt) | 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon | |
| AR028705A1 (es) | Bis-arilsulfonas | |
| EP1501531A4 (en) | METHOD FOR TREATING ANXIETY AND MOOD DISORDERS IN AGES | |
| ES2170176T3 (es) | Utilizacion de antagonistas de receptores de la serotonina y de la dopamina para el tratamiento de las enfermedades mentales resultantes de las enfermedades cerebrovasculares. | |
| BR0010515A (pt) | Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica | |
| CR6581A (es) | Pirrolcarboxamidas fundido, receptores cerebrales gaba | |
| BR0307504A (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal | |
| ES2184300T3 (es) | Derivados de aminoacidos utiles para tratar el accidente vascular encefalico. | |
| BRPI0516380A (pt) | derivados de triazolona, tetrazolona e imidazolona, composição compreendendo os mesmos, processo para sua preparação e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |